Table 1.
Dose and survival response to s50 TBG-RNAi-CK2 in mice carrying various HNSCC tumors
| SCC-15 (tongue carcinoma)# | Dosage (mg/kg) |
Dosing regimen |
Number of Mice |
6-month survival |
Mice with tumor or metastasis signala |
|---|---|---|---|---|---|
| s50 TBG-RNAi-CK2 | 50 mg/kg | 1× | 8 | 6* | 1 |
| s50 TBG-RNAi-CK2 | 50 mg/kg | 2× q 1 week | 8 | 4 | 0 |
| s50 TBG-Sense | 50 mg/kg | 1× | 8 | 1 | 1 |
| Vehicle | 1× | 8 | 1 | 1 | |
| UM-11b (laryngeal carcinoma)§ | |||||
| s50 TBG-RNAi-CK2 | 50 mg/kg 25 mg/kg | 1× ea q 48 hr | 8 | 3 | 1 |
| s50 TBG-RNAi-CK2 | 25 mg/kg | 2× q 48 hr | 8 | 6* | 2 |
| s50 TBG-Sense | 25 mg/kg | 2× q 48 hr | 8 | 4 | 3 |
| Vehicle | 2× q 48 hr | 8 | 6 | 6 | |
| FaDu (hypopharyngeal carcinoma) | |||||
| s50 TBG-RNAi-CK2 | 10 mg/kg | 2× q 48 hr | 8 | 3 | 1 |
| s50 TBG-RNAi-CK2 | 0.01 mg/kg | 2× q 48 hr | 6 | 3* | 1 |
| s50 TBG-Sense | 25 mg/kg | 1× | 8 | 0 | No survivors |
| s50 TBG-Sugar | 10 mg/kg | 2× q 48 hr | 5 | 0 | No survivors |
| Vehicle | 2× q 48 hr | 8 | 0 | No survivors |
a
Determined by luciferase imaging for all mice remaining in the survival study at 6 months as described previously12.
*
Comparison of lower to higher total s50-TBG-RNAi-CK2i dose, Log-Rank p < 0.001.
#
Comparison of % surviving mice with tumor or metastases, Fisher’s Exact p = 0.118.
§
Comparison of % surviving mice with tumor or metastases, Fisher’s Exact p = 0.058.